A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

PHASE3TerminatedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

February 21, 2022

Primary Completion Date

December 29, 2023

Study Completion Date

January 31, 2025

Conditions
Hodgkin LymphomaNon Hodgkin Lymphoma
Interventions
BIOLOGICAL

AB-205

Allogeneic genetically engineered human umbilical vein endothelial cells

OTHER

Placebo

Placebo

Trial Locations (28)

10065

Memorial Sloan Kettering Cancer Center, New York

Weill Cornell Medical College/New York Presbyterian Hospital, New York

19111

Fox Chase Cancer Center, Philadelphia

20007

Medstar Georgetown University Hospital, Washington D.C.

21201

University Of Maryland School Of Medicine, Baltimore

30322

Emory University - Winship Cancer Institute, Atlanta

33136

University of Miami - Sylvester Comprehensive Cancer Center, Miami

37203

Sarah Cannon Research Institute, Nashville, Nashville

Vanderbilt-Ingram Cancer Center, Nashville

43210

The Ohio State University Comprehensive Cancer Center, Columbus

46202

Indiana University Simon Comprehensive Cancer Center, Indianapolis

48109

University of Michigan, Ann Arbor

52242

University of Iowa Hospitals & Clinics, Iowa City

55455

University of Minnesota Medical Center, Fairview, Minneapolis

60612

University of Illinois Cancer Center, Chicago

77030

The University of Texas MD Anderson Cancer Center, Houston

80218

Sarah Cannon Research Institute, Colorado, Denver

85234

Banner MD Anderson Cancer Center, Gilbert

90095

University of California, Los Angeles, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

92093

UC San Diego Moores Cancer Center, San Diego

95817

UC Davis Comprehensive Cancer Center, Sacramento

97239

Oregon Health and Science University, Portland

98109

Fred Hutchinson Cancer Center, Seattle

33612-9416

University of South Florida (USF) - H. Lee Moffitt Cancer Center and Research Institute, Tampa

02114

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

07601

Hackensack University Medical Center, Hackensack

Sponsors
All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

Angiocrine Bioscience

INDUSTRY

NCT05181540 - A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation | Biotech Hunter | Biotech Hunter